Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

PCE

ERYTHROMYCIN

Standard Dose
333MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview PCE is listed in Drugs@FDA under application 050611 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength TABLET, COATED PARTICLES;ORAL - 333MG Sponsor AZURITY Submission history Latest submission status date: 2018-04-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview PCE is listed in Drugs@FDA under application 050611 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength TABLET, COATED PARTICLES;ORAL - 333MG Sponsor AZURITY Submission history Latest submission status date: 2018-04-23 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.